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At the core of every health economic analysis is a
model. It is the model that converts data about dis-
eases, interventions, and costs into projections of what
will happen in the future. The importance of good data
is emphasized by the expression “Garbage in, garbage
out.” With a ﬂawed model “Anything in, garbage
out.” My purpose in this commentary is to argue that
the increasing complexities of the problems we are try-
ing to analyze are pushing our current models to their
limits, and to offer a new type of model for our toolkit.
Because both the need for the model and its design are
rooted in my experiences, I will tell the story from a
personal perspective.
Need for a New Type of Model
The need for a new type of model was gradually forced
on me by the gap between the types of problems I
wanted to analyze and the capabilities of the existing
models. My own experiences began about 35 years
ago with Markov models [1]. Given the continuing
prominence of this type of model in health economic
modeling, this is a reasonable place to start.
Every reader of Value in Health is familiar with the
basic structure of a Markov model. The fundamental
property that makes a random process a Markov proc-
ess is that given the present, the future is conditionally
independent of the past. Other ways to say this are that
history does not matter, and the process has “no mem-
ory.” Typically a Markov process is deﬁned in terms of
discrete states; at any time the process will be in a par-
ticular state, and at discrete time intervals the process
can make transitions between states. A textbook
example is cars in a queue for a tollbooth. The state of
the process is the number of cars in the queue at any
time. The state changes every time a new car enters the
queue or the front car is cleared through the tollbooth,
and the trajectory of the process is determined by the
probabilities of those events.
In a typical health economic model the process is a
pathological condition such as a disease, and the states
are constructed by dividing the pathological process
into discrete stages. An example is to represent cardi-
ovascular disease (CVD) by four states: “no CVD,”
“had an MI,” “angina,” and “dead of CVD.” Another
is to represent nephropathy as “no nephropathy,”
“microalbuminurea,” “proteinuria,” “end-stage renal
disease (ESRD),” and “dead of ESRD.” Progression
from one state to another is determined by the transi-
tion probabilities, with transitions typically occurring
at annual intervals.
Markov models have some very useful qualities,
especially when compared with other types of models
such as regression equations and decision trees. The
main strength that distinguishes them from those other
models and that makes them so popular for health eco-
nomic modeling is that they are dynamic and proba-
bilistic—they can address problems in which events
and decisions are occurring, subject to chance, over
time. Other strengths are that the concept of discrete
states resonates with the labels we often use to talk
about  diseases,  such  as  a  person  having  “diabetes”
or having “hypertension.” The notion that diseases
progress from state to state is also intuitively appeal-
ing, as exempliﬁed by images of cancers progressing
from in situ, to localized, to regional metastases, and
so forth. The annual interval corresponds to many
other things that are tallied annually, such as annual
incidence rates and annual budgets. States and transi-
tions are useful hooks on which to attach costs and
quality weights. And the basic mathematical structure
of a Markov model is easy to learn, describe, and cal-
culate. In short, if the states can be deﬁned so that they
are sufﬁciently realistic for the problem to be analyzed,
if there are good data for the transition probabilities,
and if the Markov history-does-not-matter assumption
holds, then the Markov model can be a very useful
framework for calculating clinical and economic
events.
Unfortunately, the three conditions just listed are
difﬁcult to meet. The reason is that biological proc-
esses and clinical medicine are fundamentally different
than the types of processes for which Andrei Markov
designed his model. As a consequence all sorts of sim-
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pliﬁcations and assumptions have to be made to ﬁt
them into that framework. Consider ﬁrst the funda-
mental Markov assumption that history does not
matter. Everyone knows that this is patently untrue.
Imagine opening a patient’s chart and seeing only
today’s notes (e.g., today’s physical ﬁndings, today’s
lab results)—all the previous pages have been dis-
carded. The very nature of a chronic condition is that
the risk of complications, such as stenosis in arteries,
builds up over time. But the no-history assumption
requires, for example, that a person’s cholesterol-
related risk of a myocardial infarction (MI) depends
only on their current low-density lipoprotein (LDL)
level, say, 110 mg/dl, and it does not matter whether
they have always been at 110 mg/dl or they have been
at 175 mg/dl for 30 years and were just brought down
to 110 mg/dl by treatment. The same point can be
made about blood pressure, glucose, smoking and
other risk factors that lead to chronic damage. Thus,
the no-history assumption creates a problem. Either
we have to limit ourselves to problems where history
truly does not matter, which is a small list in medicine;
or we have to pretend that it does not matter and
accept whatever inaccuracies that may cause; or we
have to ﬁnd some way to overcome the assumption,
which is in essence saying that we do not like the fun-
damental piece of the Markov framework. Inciden-
tally, the same assumption of no-history is being made
every time we use an equation like the Framingham
and insert current values for cholesterols, blood pres-
sure and smoking, or change the values to estimate the
effects of treatments.
Now consider the concept of a discrete state. To
appreciate the problems here we ﬁrst need to recognize
that because the number of possible transitions grows
exponentially with the number of states, and because
data have to be found for every transition, there is a
very strong motivation to keep the number of states
down. So although in theory the Markov framework
can handle a very large number of states, in practice
they are kept to a small number, typically under a
dozen. But reducing the number of states means that
each state has to include more disparate groups of peo-
ple. This can happen in two main ways—either by
dividing a disease process into a small number of dis-
crete states, or by combining several disease processes
into a single state. Take the ﬁrst one ﬁrst. An immedi-
ate observation is that as comfortable as we might be
talking about diseases using clean labels like “heart
attack,” “diabetes,” “ESRD,” and “regional metas-
tases,” these are enormously complex conditions and
they do not jump from one discrete state to another. A
heart attack is not a single variable that switches sud-
denly from “no MI” to “MI,” like a new car entering
a queue; it is the result of a multidimensional process
that progresses continuously and is affected by a wide
variety of factors most of which themselves are con-
tinuously changing. A modeler who dichotomizes that
process into “no MI” and “MI” does not do so
because he or she believes it is accurate, but because
the discrete-state structure of a Markov model requires
this type of simpliﬁcation.
The problem of course is that the simpliﬁcations
hide a huge number of important factors that can have
profound effects on the outcomes, but that get ignored
in the calculations; imagine condensing an MI patient’s
chart down to one sentence that says “Has not had a
MI.” A trivial example is that a person with 90%
occlusion of the left anterior descending artery and a
person with clean arteries would both be in the same
state of “no MI,” and a model that recognizes only
“no MI” and “MI” will treat them as though they
were the same. We might try to ﬁx the problem by
stratifying the state in some way. But even if we look at
populations that have similar descriptions there can be
wide differences in future risks that the model cannot
see because of the simpliﬁed states. For example, let’s
narrow the state to “no MI but high risk of CAD”; the
5-year risk of MIs can still vary from 4% [2] to 6% [3]
to 8% [4] to 13% [5,6]. Consider the state “had an
MI”; the 5-year risk of a repeat MI in people with a
previous MI can vary from 13% [7,8] to 25% [9]
depending on other variables that are present in the
real population but are missed in the designation “had
a MI.” Needless to say differences like these, by factors
of 2 or 3, have disastrous consequences for an analysis.
To try to sharpen the deﬁnitions of the “no MI” and
“MI” states even further we might turn to the Fram-
ingham equation, but that maneuver only tightens the
argument I want to make, which is that the basic
Markov framework is not working for us. First, the
Framingham equation only includes a handful of var-
iables. For example it does not include such obvious
factors as family history, presence of angina, use of
aspirin, and the duration, severity or treatment of dia-
betes. Thus, although it may help solve part of the
problem, it does not solve all of it. Second, even
acknowledging its limitations we do not have equa-
tions like the Framingham for the overwhelming
majority of other conditions. Third, as already
described the Framingham equation itself makes a no-
history assumption. But the fourth and most important
point is that pulling in the Framingham equation to
save the “no MI” state is a clear statement that the “no
MI” state is too simplistic. The “no MI” state has
become a mere label for a myriad of states deﬁned on
the ﬂy by the independent variables in the Framingham
equation. It is not a Markov state any more; its only
real role is to serve as a storage point for tallying events.
The second way the number of discrete states is
kept down is by combining multiple disease processes
into a single state. For example, people who: 1) “have
had two or more depressive symptoms for at least two
weeks, and have functional impairment, but do not
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meet the Diagnostic and Statistical Manual of Mental
Disorders criteria for major depression”; 2) “have
minor depression”; 3) “have dysthymia”; or 4) “have
major depression in partial remission” may be com-
bined into a state called “signiﬁcant depressive symp-
toms.” Every clinician knows that these four clinical
conditions are in fact very different, which is why they
have different names and diagnostic criteria, as well as
different etiologies, natural histories, symptoms, treat-
ments, and prognoses. But by combining them into a
single state, we are telling the Markov model to
assume they are the same.
The transition probabilities also present problems.
In medicine they are not simple chance events; they are
the result of very complex biological phenomena and
our attempts to manage them. Indeed almost every-
thing that is interesting in medicine is happening inside
the transitions. Consider the factors that determine
whether a person jumps from “no MI” to “had an MI”
or “dead from MI.” These probabilities are deter-
mined by risk factors such as dyslipidemia, hyperten-
sion, diabetes, obesity, and smoking; interventions to
manage the risk factors; use of medications like aspi-
rin; how alert a person is to early signs and symptoms;
the availability of emergency systems and delays in get-
ting care; the role of symptoms and tests like the
EKG’s, CK-MB or Troponin in making a diagnosis;
protocols for deciding who to admit, observe or send
home; emergency treatments like aspirin, thrombolyt-
ics, percutaneous transluminal coronary angioplasty
(PTCAs), and stents; and longer-term interventions
like cholesterol lowering drugs, beta blockers, and
rehabilitation.
The importance of this complexity for building a
Markov model is profound. First, the fact that the
transition probabilities are affected by so many factors
greatly complicates the task of ﬁnding data for the
transition probabilities, essentially requiring that there
be data from other settings that match the setting we
want to address (e.g., the same population, same man-
agement of risk factors, same use of aspirin, same
triage protocols, same acute care, etc.) If even one of
these factors is off, the transition probability and
therefore the ﬁnal results will be off. For an example
consider that to get the rate of repeat MIs in people
with previous MIs one modeler might go to the CARE
trial and come back with a 5-year rate of 13% whereas
another might go to the 4-S trial and come back with
25%. Second, if we can not ﬁnd the data we need from
a matching setting, or if the problem we want to
address involves any of the things that are inside the
transition probabilities, we will need to build another
model (and ﬁnd data for it) just to calculate the tran-
sition probability in the Markov model. For example,
suppose the problem is to evaluate the use of troponin
in the work-up of people who present with chest pain
in the ER. To analyze this problem we would need to
build another model and ﬁnd data for the transition
probabilities from “no MI” to “had an MI” or “died
of MI” for each of the possible roles for troponin we
wanted to explore (e.g., Use troponin instead of CK-
MB? In addition to CK-MB? Use troponin I? Or
troponin N? Use a cutoff point of ≥0.4 ng/ml? Or
≥0.7 ng/ml?)
Finally, the use of discrete time intervals, usually
annual, also creates problems. In fact, almost nothing
real happens at annual intervals. Important clinical
events can occur over minutes or hours, as in getting
cardiopulmonary resuscitation or thrombolytics to a
person with a heart attack, or over years, as in a
healthy 30-year-old. A chronic disease like diabetes can
plod along for years with no clinical symptoms, and
then erupt with acute complications. Trying to capture
these effects in a discrete time interval puts even more
burden on the transition probabilities and states.
At this point it is very important to stress that these
limitations do not necessarily invalidate a Markov
model. But as already indicated for the no-history
assumption, they do mean one of three things: either 1)
we have to be willing to ignore the importance of these
simpliﬁcations and assumptions, and accept whatever
inaccuracies they may create; 2) we have to restrict
ourselves to applications that are truly not affected by
the limitations (e.g., it truly does not matter that we
are lumping together all people with MIs or all people
with “signiﬁcant depressive symptoms”); or 3) we
have to build additional models to address each of the
important factors, essentially replacing the transition
probabilities and the states with other models. The ﬁrst
is unacceptable and the second is giving up on a large
class of problems. The third is the only acceptable way
to use a Markov framework to answer important ques-
tions. But it leads to other problems.
To illustrate these problems I will pick on my own
work. Around 30 years ago the American Cancer Soci-
ety asked me to help them update their recommenda-
tions for cancer screening. I built a Markov model to
calculate the costs and effectiveness of different screen-
ing strategies [10,11]. The model was successful in the
sense that its results caused major changes in the rec-
ommendations [12], some of which are still reverber-
ating today (e.g., the 3-year Pap smear, 3- to 5-year
colon cancer screening, no routine sputum cytology or
chest x-rays even for smokers, mammography only for
women over age 50). The analysis introduced concepts
of modeling, evidence, and cost-effectiveness into
national guidelines [11]. The resulting guidelines
attracted considerable public attention [13]. The pre-
dictions made by the model were validated against an
independently collected data set 6 years later [14].
So what’s the problem? The problem is that
extraordinary mathematical contortions were needed
to stuff the cancer-screening problem into the Markov
framework. We have already seen that the Markov
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framework involves discrete states and assumes no
memory. In contrast, in the cancer-screening problem
virtually everything changes continuously and nothing
obeys the Markov no-memory assumption. Cancers
are continuously changing over time; there are multi-
ple tests that can be carried out in any order or fre-
quency—and not necessarily together or annually; the
sensitivities of the screening tests vary depending on
how  far  the  cancers  have  advanced  (e.g.,  the  size  of
a breast mass); the cancers can become apparent
between scheduled screening tests through self exami-
nation or symptoms; the prevalence of detectable but
not yet detected cancers depends on the past use of the
tests and patient self detection; how early the cancers
are detected also depends on those factors; the effec-
tiveness and costs of treatments depend on how early
the cancers are detected, and so forth. To accommo-
date all these factors within the Markov structure I had
to build sub models that redeﬁned every state and
recalculated every transition probability on the ﬂy. It
required dozens of differential equations, and a 250-
page book to describe it all [15]. Although the ﬁnal
model was a Markov model in the sense that it used
states and transitions, all the heavy lifting was done by
the differential equations whirring in between every
transition. The amount of new mathematics needed to
get around the limitations of the Markov structure is
indicated by the fact that the model won a prize for the
most important contribution in the English language
to the ﬁelds of operations research and management
science [16].
The point is that somewhere down the line one has
to stop and ask oneself, “If I have to go through so
many gyrations to ﬁt a problem into a Markov frame-
work, am I really using the right model? Maybe there
is some other mathematical formulation that is a better
ﬁt to biological and clinical problems.”
Design of a New Type of Model
And of course there is. It is calculus, developed more
than 300 years ago by either Isaac Newton or Gottlieb
Leibniz depending on which side of the Channel you’re
on. Indeed, if one looks at my screening model with a
fresh eye it is obvious that it is really a set of differen-
tial equations and the Markov structure is little more
than a framework for tabulating the events and costs.
I was not using the Markov properties—no history,
discrete states, or discrete time—at all. In fact I was
doing everything I could to get around them. Further-
more, by breaking up the progression of the cancers
into artiﬁcial states the Markov structure was creating
unnecessary and damaging constraints. Why not just
shuck off the Markovian constraints and simply build
the model directly in differential equations?
This theme kept recurring in my subsequent work
on guidelines, coverage policies, performance meas-
ures, quality improvement, cost-effectiveness, and
related topics. Over time, it became more and more
apparent that, at least for the problems that I was try-
ing to address, a new type of model was needed.
Gradually, the following motivations and design
criteria emerged. First, to help clinicians make deci-
sions; to help design guidelines, performance meas-
ures, and the “what-to-do” parts of disease
management programs; and to be credible, the model
had to start at the level of physiological and clinical
detail at which clinicians think. Essentially, it had to
encompass all the biological variables that physicians
consider to be important in the management of their
patients. This level of detail would also be required to
help analyze the physiological processes underlying
diseases and their treatments, and to help design, inter-
pret, and extend clinical trials. Second  to  address
issues  that  arise  in  the  design  of  the “how-to-do-it”
parts of disease management programs, case manage-
ment protocols, and continuous quality improvement
projects, the model had to include care processes,
logistics, and behaviors at an equally high level of
detail. This is also needed to translate idealized clinical
trial results into realistic settings. Third, to provide
credible information about logistics and cost effective-
ness, it had to include system resources such as facili-
ties, personnel, visits, admissions, equipment, and all
their costs. It should be able to track events and their
costs just as is done in real health-care systems. Fourth,
to help set clinical priorities, design strategic goals, and
prioritize and/or combine performance measures, the
model had to be able to span across all types of inter-
ventions (primary prevention, screening, diagnosis,
treatment, secondary prevention, and support care)
and span multiple diseases using the same methodol-
ogy. A broad span would also be required to address
patients who have multiple diseases (comorbidities),
syndromes that affected multiple organ systems, drugs
that have multiple effects, and combinations of drugs.
Fifth, to address questions of timing—such as screen-
ing, frequency of follow-up visits, or how long a med-
ication should be tried before the dose is changed—the
model had to function in continuous time, and be able
to address events that can change as rapidly as minute
by minute, or as slowly as years. Finally to be credible,
the model had to be able to simulate most important
epidemiological studies and clinical trials at the level of
clinical detail at which they are designed and reported,
and match or predict their results within the appropri-
ate sampling errors.
It was already clear that differential equations are
the natural way to represent the continuous changes
and interactions of biological variables. The next ques-
tion was whether there are better ways to represent all
the other aspects of a health-care system such as pro-
tocols, care processes, providers, visits, resources, and
costs. And again, there are. One is object-oriented pro-
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gramming (OOP). Although much younger than cal-
culus—about 35 years old—it is very powerful and
versatile, being the programming method behind such
disparate things as graphical user interfaces, Excel, air-
line reservation systems, video games, and Defense
Department  models  of  the  European  war  theater.  It
can handle very high levels of complexity and detail,
although remaining ﬂexible and easy to update. It was
an obvious choice for a framework for health eco-
nomic modeling.
The Archimedes Model
The use of differential equations and OOP can be
illustrated with the Archimedes model, which a team
led by Len Schlessinger and me has been developing
over the last 12 years. The mathematical formulation
and a clinical overview of the model have been
described elsewhere [17,18]. Examples of speciﬁc
equations and sources are available through our Web
site (http://www.archimedesmodel.com). Brieﬂy, the
Archimedes model uses differential equations, OOP,
and a modeling concept we call “features” to repre-
sent human physiology at a level of detail roughly
comparable to that found in general medical text-
books or patient charts. For example, for analyzing
something like the metabolic syndrome the model
includes variables relating to glucose metabolism
(hepatic glucose production, uptake of glucose by fat
and muscle, insulin amount, insulin resistance, fasting
plasma glucose [FPG], HbA1c, and 2-h OGT); lipids
(e.g., LDL, high-density lipoprotein [HDL], triglycer-
ides, LDL particle size, and number); obesity (body
mass index [BMI] and waist circumference); inﬂam-
mation (e.g., C-reactive protein); blood pressure (e.g.,
cardiac output, arterial compliance, peripheral resist-
ance); coronary artery disease (e.g., gradual stenosis,
plaque rupture, myocardial ischemia); strokes (hem-
orrhagic and ischemic); as well as models of nephro-
pathy, retinopathy, and neuropathy. Time is
continuous, all the biological variables are continuous
functions of time, and any event can occur at any
time. The model includes multiple organ systems and
diseases as part of a single physiology. It also includes
a detailed representation of other part of the health-
care system, as described in the design criteria listed
in a previous paragraph.
Our objective is to create a virtual world that can be
used for such things as exploring the effects of guide-
lines, disease management programs, performance
measures, and quality improvement programs; design-
ing, predicting, and interpreting clinical trials; fore-
casting clinical and economic outcomes; setting
priorities; and estimating person-speciﬁc outcomes.
The scope of potential applications is most easily
described by listing some of the actual applications in
the past year.
• “How does treating insulin resistance directly
compare with treating hyperglycemia? (Insulin
resistance affects not only glucose but also triglyc-
erides, HDL, BP and other variables.);
• “What would be the effect on biological variables
and clinical outcomes of a drug that decreases
weight by x%? For what populations would such
a drug be best indicated?
• “How does delivering insulin through inhalation
compare with the current method of injection?
What are the implications of the different effects
on HbA1c for downstream clinical outcomes?
What trial should we conduct to determine the
appropriate indications?
• “Is there an underlying cause of the metabolic syn-
drome? What are the roles of insulin resistance,
inﬂammation, adiponectin, LDL particle size,
apolipoprotein B, and ﬁbrinogen? What propor-
tion of CVD events can be attributed to the met-
abolic syndrome compared with nonmetabolic
causes such as sex, age, race/ethnicity, and smok-
ing? How should the metabolic syndrome be
deﬁned?
• “We want a calculator that will tell people their
risks of diabetes and its complications, taking into
account not only the usual Framingham type var-
iables (sex, age, SBP, TC/HDL, smoke? diabetes?),
but also duration and severity of diabetes, past
medical history (e.g., previous MI), past treat-
ments, past and current weight/BMI, current
symptoms and complications, and current
medications.
• “What are the relative effects of raising perform-
ance from the average to the 90th percentile level
for each of the HEDIS measures for CVD, diabe-
tes, CHF and tobacco? If we can only focus on ﬁve
measures, which are the most important?
• “We’ve done a phase II trial that showed these
results . . . What would a phase III trial show for
clinical outcomes? What would happen in differ-
ent populations (i.e., different indications)? What
is the optimal design for a trial?
• “We want to combine two drugs, but we are not
willing to assume the effects are additive or mul-
tiplicative. What will be its effects in populations
that have different initial risks, different current
treatments, and different current degrees of
control?
• “There is a trial in progress that will be reported
in the AHA meeting in two months. We want you
to predict its results so we can plan.”
A frequently asked question about the Archimedes
model is whether the high level of physiological detail
is really required. The answer depends on what types
of questions you want the model to be able to address.
For us the answer is in the projects just listed. If we
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want to be able to address the metabolic syndrome,
then the model has to include insulin resistance, adi-
ponectin, C reactive protein, etc. If we want to study
the cost-effectiveness of various strategies for meeting
Health Employer Data Information Set (HEDIS) tar-
gets, then the model has to include the HEDIS varia-
bles, their tests, and treatments, and all the logistics
that will be affected. It also has to include all the per-
tinent conditions (e.g., CVD, diabetes, congestive heart
failure [CHF]) in a single integrated model. If you want
to analyze a disease management program for CHF
that uses an ejection fraction <50% as one of the cri-
teria for selecting patients, the model has to include
ejection fractions and all the physiology around it. Our
criterion is that if the people who know the ﬁeld and
will use the model believe a variable is important, and
if the data support them, we want to include it. Stated
another way, we want the details of the questions to
determine the details of the model, not the other way
around.
Validation of the Model
Archimedes illustrates the type of model that can be
built with differential equations, OOP, and features.
But it also raises a question. How can we determine
whether it works? That is, how can we know whether
its results are accurate in predicting what will actually
occur? To answer this we need to go back to the sci-
entiﬁc method, the foundation of which is observation
of real events. We need to use the model to simulate
actual events that occur in the real world, and then
compare the model’s results to the real results.
To test the Archimedes model the real results we
have chosen to compare ourselves to are clinical trials
[19], although we also use epidemiological studies and
smaller studies to check parts of a model. We chose
clinical trials for the same reasons they are so valuable
in other aspects of medicine; they are the most rigorous
and best-documented way to determine what is really
happening. Clinical trials are the foundation on which
the clinical practice of medicine it built, and by simu-
lating them we are helping ensure that the model
anchored just as strongly to that foundation. Method-
ologically, simulating clinical trials also has the virtue
of testing an entire model—from the characteristics,
behaviors, histories, and past treatments of the popu-
lation; through the occurrence of symptoms, visits,
tests, diagnoses, and treatments; and ﬁnally to the
occurrence of the clinical outcomes.
Brieﬂy, the steps are: 1) use the inclusion and exclu-
sion criteria as well as information on the distribution
of characteristics, biological variables, current and
past medical histories, medications, and behaviors
(what is often in “Table 1” of published reports of tri-
als) to select a simulated population that matches the
real population; 2) give this population interventions
according to the protocols of the trial; 3) run the
model; 4) measure the outcomes that deﬁne the end-
points of the trial, using the deﬁnitions and measure-
ment protocols speciﬁed for the trial; and 5) compare
the model’s results to the results seen in the real trial.
Although our main focus is on the primary and sec-
ondary endpoints deﬁned for each trial, we also check
the model’s accuracy for calculating biological out-
comes. All of the simulations are performed at the
highest level of detail of which the model is capable.
For example, if two trials reported retinopathy out-
comes but one measured two-step retinopathy [20],
whereas the other measured three-step retinopathy
[21], we have the simulated physicians do simulated
eye exams on each simulated patient using the partic-
ular protocol that applies to each trial.
To avoid obvious selection and reporting biases we
have an independent committee pick the trials and
monitor the results; for the ﬁrst round of validations
the American Diabetes Association set up the commit-
tee. The trials are the major ones that pertain to the
questions the model will be used to address; in this
case, those relating to diabetes and its complications.
The validations are performed with the same version
of the model, as the results would be meaningless if the
model were revised each time to make it ﬁt each trial.
We try to ﬁnd enough trials should so that they “tri-
angulate” the problems for which the model is to be
applied; we want to validate the model against at least
one trial that involves the same population, at least one
that involves the same treatments, and at least one that
involves the same types of outcomes. And we want as
many of the trials as possible to be independent in that
they were not used to build the model. For the ﬁrst
round, 40 of the 74 validation exercises were
independent.
Examples of results for the Archimedes model are
shown in Figures 1–6. Figures 1 and 2 evaluate the
model’s ability to reproduce biological outcomes, in
this case the average FPG levels. Figure 1 illustrates the
results for the UK Prospective Diabetes Study (UKPDS)
trial of conservative versus intensive management of
glucose in people with newly diagnosed diabetes.
Because we used some information from the UKPDS
trial to help build the Archimedes model, this is a
dependent validation. An example of an independent
validation of biological outcomes is the Diabetes Pre-
ventions Program (DPP), which evaluated the effects of
placebo versus metformin versus intensive lifestyle
modiﬁcation in people with prediabetes [22] (Fig. 2).
Figure 3 illustrates the calculation of a clinical out-
come, the rate of coronary artery events in the UKPDS
(another dependent validation). An example of an
independent validation for a clinical outcome is the
Heart Protection Study [5] in which adults at high risk
of MI because of high LDL, other arterial occlusive
disease or diabetes were treated with simvastatin or a
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Figure 1 Fasting plasma glucose in the control
group of UK Prospective Diabetes Study: com-
parison of trial and model. FPG, fasting plasma
glucose.
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Figure 2 Fasting plasma glucose in the Diabe-
tes Preventions Program trial.
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Figure 3 UK Prospective Diabetes Study:
myocardial infarction (fatal and nonfatal).
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Figure 4 Major coronary events in the Heart
Protection Study.
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Figure 5 Archimedes prediction of Diabetes
Prevention Program results.
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Figure 6 Archimedes prediction of Collabora-
tive Atorvastatin Diabetes Study trial: major
coronary events.
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placebo (Fig. 4). When possible we try to predict the
results of trials before their results are known or pub-
lished. Two examples are the DPP (Fig. 5) and the
Collaborative Atorvastatin Diabetes Study trial [23]
that compared atorvastatin versus placebo in people
with diabetes (Fig. 6). Results for 15 other trials are
described elsewhere [19]. Overall, the correlation
between the model’s results and the real results is
about 0.98. Our practice is to continue to test the
model against new trials as they appear, or if they
become important benchmarks for new analyses.
Thus, far the Archimedes model has been validated
against 28 trials.
Validations like these do not promise that every
new analysis or prediction with the model will be per-
fectly accurate, but they do at least demonstrate that a
model built at a high level of detail using differential
equations, OOP, and features can be reasonably accu-
rate in representing what is currently known from
existing trials. The relatively high success rate with
more than 40 independent validation exercises
(r2 = 0.96) also suggests that existing information, at
least as it is represented in the Archimedes model, is
reasonably complete in enabling predictions of new tri-
als the model has never seen. This is encouraging,
because clinical trials are very analogous to the types
of problems we are building the model to address; like
real problems they involve speciﬁc populations given
speciﬁc interventions using speciﬁc protocols to affect
speciﬁc results. It is also encouraging for medicine in
general.
We need to emphasize that there will always be mis-
matches and surprises with any model. That should
not upset anyone. Indeed, the whole purpose of con-
ducting new clinical trials is to ﬁnd results that cannot
be predicted with existing information. In our experi-
ence, there have been two occasions out of more than
40 independent validation exercises when the model’s
results did not “statistically match” the real results: the
rate of MIs in the control group of the WOSCOPS trial
of pravastatin versus placebo in high-risk men in west-
ern Scotland, and the effect of atorvastatin on the rate
of strokes in people with diabetes. When this occurs,
we determine the cause and if necessary use the new
information to improve the model. We then look for
other studies to independently validate the modiﬁca-
tions. Continuous application of this process gradually
expands and improves the model.
Conclusions
Different models have different strengths and weak-
nesses. The task of the modeler is to ﬁnd the best type
of model to match the characteristics of the system to
be represented and the problem to be solved. Regres-
sion models are excellent methods for mining data sets
and identifying relationships between variables. Deci-
sion trees are powerful ways to select between options
to maximize expected value and take into account risk
aversion. Similarly, Markov models can be powerful
tools for representing systems that are dynamic and
probabilistic. The fact that many health economic
problems are also dynamic and probabilistic makes it
an obvious choice for this ﬁeld.
But each type of model also has limitations. Here
the task of the modeler is to understand the limita-
tions and either restrict the application of the model to
problems that stay within the limitations, or modify
the model to get around the limitations. An unfortu-
nate fact about Markov models is that several of its
fundamental properties—a process whose future is
conditionally independent of the past, characteriza-
tion of a process as discrete states, representation of
movements between states as simple transition proba-
bilities, and cutting time into discrete intervals—are
not a good match to biological systems and clinical
problems. Mathematicians have been ingenious in
developing methods to expand the capabilities of the
Markov framework, with such things as semi-Markov
continuous, partially observable and hidden Markov
processes. For at least 30 years people have been add-
ing decision nodes, bridge models, and parallel models
to address the special needs of health care. But as we
try  to  push  the  Markov  model  farther  and  farther,
the simpliﬁcations and assumptions we have to make
become more and more troubling, the modiﬁcations
we have to make to get around the simpliﬁcations and
assumptions become more and more difﬁcult, and the
results become more and more suspect. At some point,
it is appropriate to ask whether there is not a better
way.
In our experience there is a class of important prob-
lems that push the Markov framework beyond its
intended limits. Indications that the limits are being
reached are problems that involve one or more of the
following:
• Diseases that are multifactorial and not well rep-
resented as a single process. Diseases that are too
complex to be well described by a small number of
discrete states.
• Diseases in which past medical history is
important.
• The need to represent the underlying biology of a
condition or mechanism of action of a drug on
biological outcomes.
• Clinical processes such as guidelines, disease man-
agement, and quality improvement programs
where the steps in the process have implications
for effectiveness, costs or logistics.
• Comorbidities and syndromes that affect multiple
organ systems and outcomes.
• Drugs with multiple effects and combinations of
drugs.
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• Cost effectiveness problems in which it is impor-
tant to include logistics such as tests, treatments,
visits, admissions, etc.
• Problems where patient and/or physician behav-
iors are important. Problems where the effective-
ness of the intervention in realistic settings may be
different from settings of clinical trials because of
differences in behaviors.
• Problems where errors in tests and treatments are
important.
• Problems where timing is important, such as
screening, timing follow-up visits, or decisions
about how long to keep a patient on a treatment
before modifying it or switching to another.
Diseases in which important events unfold unevenly
over time, such as chronic diseases that have occa-
sional acute events:
• Problems that span multiple diseases and/or inter-
ventions, such as setting priorities.
• Problems that involve performance, such as per-
formance measures and pay for performance.
For problems like these we have found it necessary
to design a new type of model that combines differen-
tial equations, OOP, and features. We believe this
approach is new, at least in health. A PubMed search
for text words “differential equations” and “object
oriented” begins with our 2003 article. Since then
three additional articles have been published applying
differential equations and object oriented methods to
cell simulation. The offer then is that if others ﬁnd
themselves facing similar constraints with other types
of models, they might ﬁnd it useful to try this
approach.
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